Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1[S]

The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy...

Full description

Bibliographic Details
Published in:Journal of Lipid Research
Main Authors: D.Lee Gorden, David S. Myers, Pavlina T. Ivanova, Eoin Fahy, Mano R. Maurya, Shakti Gupta, Jun Min, Nathanael J. Spann, Jeffrey G. McDonald, Samuel L. Kelly, Jingjing Duan, M.Cameron Sullards, Thomas J. Leiker, Robert M. Barkley, Oswald Quehenberger, Aaron M. Armando, Stephen B. Milne, Thomas P. Mathews, Michelle D. Armstrong, Chijun Li, Willie V. Melvin, Ronald H. Clements, M.Kay Washington, Alisha M. Mendonsa, Joseph L. Witztum, Ziqiang Guan, Christopher K. Glass, Robert C. Murphy, Edward A. Dennis, Alfred H. Merrill, Jr., David W. Russell, Shankar Subramaniam, H.Alex Brown
Format: Article
Language:English
Published: Elsevier 2015-03-01
Subjects:
diagnostic tools
mass spectrometry
phospholipids
sphingolipids
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520356005

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520356005

Similar Items